O'Brien Patrick's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Jan 5, 2023
- Accession no.
- 0001209191-23-002114
- Filed
- Jan 5, 2023
- Trade date
- Jan 3-4, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market sales total $670.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Brien PatrickCIK 0001627183 | Officer (COO and General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Common Stock | SSaleDisposed | −2,653 | $37.53 | −$99,567.09 | 378,222 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −5,527 | $38.54 | −$213,010.58 | 372,695 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −500 | $39.74 | −$19,870 | 372,195 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −70 | $40.80 | −$2,856 | 372,125 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −2,894 | $37.58 | −$108,756.52 | 369,231 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −5,286 | $38.58 | −$203,933.88 | 363,945 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −300 | $39.55 | −$11,865 | 363,645 | Direct | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −270 | $40.53 | −$10,943.1 | 363,375 | Direct | |
| Jan 4, 2023 | Common Stock | AGrant or awardAcquired | +65,000 | $0.00 | $0 | 428,375 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.